Paclitaxel Induces Apoptosis in AIDS-Related Kaposi's Sarcoma Cells

Paclitaxel is a microtubule stabilizing drug that causes dividing cells to arrest and then undergo apoptosis. It also has antiangiogenic activity because it alters cytoskeletal structure, affecting migration and invasion. Paclitaxel is an effective treatment for AIDS-related Kaposi’s sarcoma (KS). KS is a tumor in which there is marked proliferation of endothelial cells in addition to the tumor cells, which themselves share many markers with activated (proliferating) endothelial cells.We sought to determine the mechanism by which paclitaxel exerts its anti-KS tumor effects. In vitro, KS cells are very sensitive to paclitaxel, with half-maximal growth inhibition observed at 0.8 nM. Inhibition of migration of KS cells was also observed at nanomolar concentrations of the drug. Paclitaxel induced cell cycle arrest with an accumulation of cells in sub-G1.This was accompanied in vitro by various events typical of apoptosis: phosphorylation of two anti-apoptotic proteins Bcl-2 and Bcl-xL , release of cytochrome c into the cytoplasm, cleavage and activation of caspase-3. In vitro results were borne out by studies of KS tumor xenografts in nude mice. Paclitaxel (10 mg/kg) inhibited tumor growth by 75% over 21 days. Histological examination of the tumors revealed a decrease in proliferative index, a decrease in the number of mitotic figures and an increase in apoptotic cells compared to tumors from untreated mice.

[1]  D. Ablashi,et al.  Seroepidemiology of Kaposi's sarcoma-associated herpesvirus (KSHV). , 1999, Seminars in cancer biology.

[2]  D. Mullins,et al.  Paclitaxel enhances macrophage IL-12 production in tumor-bearing hosts through nitric oxide. , 1999, Journal of immunology.

[3]  A. Tulpule,et al.  Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi's sarcoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  M. Ott,et al.  Paclitaxel shows cytotoxic activity in human hepatocellular carcinoma cell lines. , 1999, Cancer letters.

[5]  M. Mildner,et al.  Expression of vascular endothelial growth factor receptor-3 and podoplanin suggests a lymphatic endothelial cell origin of Kaposi's sarcoma tumor cells. , 1999, Laboratory investigation; a journal of technical methods and pathology.

[6]  S. Leach,et al.  Mitotic Phosphorylation of Bcl-2 during Normal Cell Cycle Progression and Taxol-induced Growth Arrest* , 1998, The Journal of Biological Chemistry.

[7]  S. Korsmeyer,et al.  Enforced dimerization of BAX results in its translocation, mitochondrial dysfunction and apoptosis , 1998, The EMBO journal.

[8]  B. Nathwani,et al.  Evidence for multiclonality in multicentric Kaposi's sarcoma. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[9]  K. Harvey,et al.  Commitment and Effector Phases of the Physiological Cell Death Pathway Elucidated with Respect to Bcl-2, Caspase, and Cyclin-Dependent Kinase Activities , 1998, Molecular and Cellular Biology.

[10]  J C Reed,et al.  Bax directly induces release of cytochrome c from isolated mitochondria. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[11]  P. Monini,et al.  gamma-Interferon produced by CD8+ T cells infiltrating Kaposi's sarcoma induces spindle cells with angiogenic phenotype and synergy with human immunodeficiency virus-1 Tat protein: an immune response to human herpesvirus-8 infection? , 1998, Blood.

[12]  G. Tortora,et al.  Synergistic inhibition of growth and induction of apoptosis by 8-chloro-cAMP and paclitaxel or cisplatin in human cancer cells. , 1997, Cancer research.

[13]  S. Srinivasula,et al.  Cytochrome c and dATP-Dependent Formation of Apaf-1/Caspase-9 Complex Initiates an Apoptotic Protease Cascade , 1997, Cell.

[14]  G. Kroemer.  The proto-oncogene Bcl-2 and its role in regulating apoptosis , 1997, Nature Medicine.

[15]  L. Liotta,et al.  Monoclonal origin of multicentric Kaposi's sarcoma lesions. , 1997, The New England journal of medicine.

[16]  K. Bhalla,et al.  Bcl-xL overexpression inhibits progression of molecular events leading to paclitaxel-induced apoptosis of human acute myeloid leukemia HL-60 cells. , 1997, Cancer research.

[17]  Dean P. Jones,et al.  Prevention of Apoptosis by Bcl-2: Release of Cytochrome c from Mitochondria Blocked , 1997, Science.

[18]  G. Viale,et al.  The microtubule-affecting drug paclitaxel has antiangiogenic activity. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  K. Bhalla,et al.  Bcl-xL overexpression inhibits taxol-induced Yama protease activity and apoptosis. , 1996, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[20]  P. Hofschneider,et al.  Oncogenesis in HIV-infection. , 1996, International journal of oncology.

[21]  W. B. Derry,et al.  Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. , 1996, Cancer research.

[22]  John Calvin Reed.  Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance. , 1995, Current opinion in oncology.

[23]  Seamus J. Martin,et al.  Protease activation during apoptosis: Death by a thousand cuts? , 1995, Cell.

[24]  M. Reitz,et al.  Isolation and characterization of an immortal neoplastic cell line (KS Y-1) from AIDS-associated Kaposi's sarcoma. , 1995, Journal of the National Cancer Institute.

[25]  W. Wilson,et al.  Treatment of HIV-associated Kaposi's sarcoma with paclitaxel , 1995, The Lancet.

[26]  B. Ensoli,et al.  Cytokines from activated T cells induce normal endothelial cells to acquire the phenotypic and functional features of AIDS-Kaposi's sarcoma spindle cells. , 1995, The Journal of clinical investigation.

[27]  W. Hunter,et al.  Controlled delivery of taxol from microspheres composed of a blend of ethylene-vinyl acetate copolymer and poly (d,l-lactic acid). , 1995, Cancer letters.

[28]  M. Raffeld,et al.  Block of AIDS-Kaposi's sarcoma (KS) cell growth, angiogenesis, and lesion formation in nude mice by antisense oligonucleotide targeting basic fibroblast growth factor. A novel strategy for the therapy of KS. , 1994, The Journal of clinical investigation.

[29]  S. Korsmeyer,et al.  Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell death , 1993, Cell.

[30]  R. Donehower,et al.  Taxol: a novel investigational antimicrotubule agent. , 1990, Journal of the National Cancer Institute.

[31]  E. Rubinstein,et al.  Kaposi's sarcoma in immunosuppression possibly the result of a dual viral infection , 1990, Cancer.

[32]  D. Ettinger,et al.  Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. , 1989 .

[33]  W. Mellado,et al.  Taxol: Mechanisms of Action and Resistance a , 1986, Journal of the National Cancer Institute. Monographs.

[34]  J. Dichgans,et al.  Taxol-mediated augmentation of CD95 ligand-induced apoptosis of human malignant glioma cells: association with bcl-2 phosphorylation but neither activation of p53 nor G2/M cell cycle arrest. , 1998, British Journal of Cancer.

[35]  R. D'Amato,et al.  Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. , 1997, Cancer research.

[36]  K. Bhalla,et al.  Taxol induces internucleosomal DNA fragmentation associated with programmed cell death in human myeloid leukemia cells. , 1993, Leukemia.

[37]  Z. Darżynkiewicz,et al.  Features of apoptotic cells measured by flow cytometry. , 1992, Cytometry.